Skip to search formSkip to main contentSkip to account menu

pazopanib

Known as: Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, Pazopanibum 
A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (3)

GW 786034BGW786034Votrient
Mast/Stem Cell Growth Factor Receptor Kit, humanNCIt Antineoplastic Agent TerminologyPazopanib HydrochloridePlatelet-Derived Growth Factor Receptor

Broader (2)

PyrimidinesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
4506Background: PAZ is indicated for the treatment of aRCC. The combination of an anti-angiogenic agent and immunotherapy may… 
2016
2016
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Review
2015
Review
2015
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.
Review
2015
Review
2015
Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
2014
2014
Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its… 
Review
2013
Review
2013
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Review
2011
Review
2011
Antiangiogenic therapies in epithelial ovarian cancer.
BACKGROUND Angiogenesis is a critical component of tumor development and proliferation, and increased angiogenesis has been… 
Review
2011
Review
2011
Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid
Introduction: Vinca alkaloid agents have been widely used in several different types of malignancies. However, cancer cells… 
Review
2011
Review
2011
Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Highly Cited
2007
Highly Cited
2007
Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study
5561 Background: Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)